TW202325277A - 含阿普司特水合物製劑 - Google Patents

含阿普司特水合物製劑 Download PDF

Info

Publication number
TW202325277A
TW202325277A TW111148936A TW111148936A TW202325277A TW 202325277 A TW202325277 A TW 202325277A TW 111148936 A TW111148936 A TW 111148936A TW 111148936 A TW111148936 A TW 111148936A TW 202325277 A TW202325277 A TW 202325277A
Authority
TW
Taiwan
Prior art keywords
apremilast
hydrate
storage
lubricant
examples
Prior art date
Application number
TW111148936A
Other languages
English (en)
Chinese (zh)
Inventor
池治宣晃
黒川剛志
Original Assignee
日商澤井製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商澤井製藥股份有限公司 filed Critical 日商澤井製藥股份有限公司
Publication of TW202325277A publication Critical patent/TW202325277A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111148936A 2021-12-23 2022-12-20 含阿普司特水合物製劑 TW202325277A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-209906 2021-12-23
JP2021209906 2021-12-23

Publications (1)

Publication Number Publication Date
TW202325277A true TW202325277A (zh) 2023-07-01

Family

ID=86902426

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111148936A TW202325277A (zh) 2021-12-23 2022-12-20 含阿普司特水合物製劑

Country Status (3)

Country Link
JP (1) JPWO2023120466A1 (https=)
TW (1) TW202325277A (https=)
WO (1) WO2023120466A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
ES2711100T3 (es) * 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
US9765026B2 (en) * 2015-08-28 2017-09-19 Scinopharm Taiwan, Ltd. Forms of apremilast and the process of making the same
US20200330433A1 (en) * 2017-10-10 2020-10-22 Mankind Pharma Ltd. Extended release pharmaceutical composition of apremilast
WO2019116386A1 (en) * 2017-12-12 2019-06-20 Alkem Laboratories Ltd. Oral pharmaceutical compositions of amorphous apremilast and process for preparing thereof

Also Published As

Publication number Publication date
WO2023120466A1 (ja) 2023-06-29
JPWO2023120466A1 (https=) 2023-06-29

Similar Documents

Publication Publication Date Title
JP2023086960A (ja) 炭酸ランタンを含有する安定な口腔内速崩壊性錠剤
JP5798642B2 (ja) 経口用医薬組成物
ES2354030T3 (es) Preparación farmacéutica sólida que comprende benzacepinas, y procedimiento de producción de la misma.
JP2025120468A (ja) イストラデフィリン製剤
JP7023054B2 (ja) レベチラセタム含有医薬組成物及びその製造方法
EP4023215A1 (en) A film coated tablet comprising teriflunomide
JP2020200348A (ja) 光安定性を向上したシロドシン含有着色錠剤
JP7161176B2 (ja) 口腔内崩壊錠及びその製造方法
TW202325277A (zh) 含阿普司特水合物製劑
JP4759102B2 (ja) 経口投与用医薬組成物
JP5823592B2 (ja) 安定性が改善された製剤
JP2020147529A (ja) ダビガトランエテキシラートを含む製剤および安定化方法
JP2017206488A (ja) ゲフィチニブ錠剤およびゲフィチニブ錠剤の製造方法
JP2022184669A (ja) テネリグリプチン含有医薬組成物
JPWO2020045607A1 (ja) 経口投与用医薬組成物
WO2022085015A1 (en) A solid oral composition of teriflunomide
JP5065519B1 (ja) 結晶性アトルバスタチンカルシウム含有錠剤の製造方法
JP7660352B2 (ja) アトルバスタチンカルシウム水和物及びエゼチミブを含む錠剤
JPWO2015199115A1 (ja) 経口投与用医薬組成物
JP2007161588A (ja) フェノフィブラートの固体分散体及びこれを含む高脂血症治療剤
JP6411265B2 (ja) エンタカポン含有医薬組成物
JP2019182859A (ja) 口腔内崩壊錠
TW201431553A (zh) Ｎ－［５－［２－（３，５－二甲氧基苯基）乙基］－２ｈ－吡唑－３－基］－４－［（３ｒ，５ｓ）－３，５－二甲基哌□－１－基］苯甲醯胺之醫藥調配物
JP2021181437A (ja) イストラデフィリン製剤
JP2009084242A (ja) 安定性に優れた塩酸テモカプリル錠剤